Cargando…
European Association for the Study of the Liver and French hepatitis C recent guidelines: The paradigm shift
The latest Association Française pour l’Etude du Foie - French Association for Study of the Liver (AFEF) and European Association for the Study of the Liver (EASL) recommendations announce a change of paradigm, for the management of patients infected with hepatitis C virus (HCV). The AFEF recommenda...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206148/ https://www.ncbi.nlm.nih.gov/pubmed/30386457 http://dx.doi.org/10.4254/wjh.v10.i10.639 |
_version_ | 1783366312161968128 |
---|---|
author | Loustaud-Ratti, Véronique Debette-Gratien, Marilyne Carrier, Paul |
author_facet | Loustaud-Ratti, Véronique Debette-Gratien, Marilyne Carrier, Paul |
author_sort | Loustaud-Ratti, Véronique |
collection | PubMed |
description | The latest Association Française pour l’Etude du Foie - French Association for Study of the Liver (AFEF) and European Association for the Study of the Liver (EASL) recommendations announce a change of paradigm, for the management of patients infected with hepatitis C virus (HCV). The AFEF recommendations focus on the elimination of HCV infection on a national level by preventing reinfection, in less than ten years. This goal involves the facilitation of patients’ management in a simplified pathway by increasing screening procedures and access to pangenotypic treatments mainly in the “reservoir” population of people who inject drugs and migrants. Even in the complex pathway of patients with previous comorbidities, AFEF takes the option of a therapeutic simplification. The EASL guidelines position themselves on the state of the art with a precise description of all therapeutic options available, without separating simplified and complex pathways even if they take into account the epidemiological evolution of difficult-to-treat populations. |
format | Online Article Text |
id | pubmed-6206148 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-62061482018-10-31 European Association for the Study of the Liver and French hepatitis C recent guidelines: The paradigm shift Loustaud-Ratti, Véronique Debette-Gratien, Marilyne Carrier, Paul World J Hepatol Editorial The latest Association Française pour l’Etude du Foie - French Association for Study of the Liver (AFEF) and European Association for the Study of the Liver (EASL) recommendations announce a change of paradigm, for the management of patients infected with hepatitis C virus (HCV). The AFEF recommendations focus on the elimination of HCV infection on a national level by preventing reinfection, in less than ten years. This goal involves the facilitation of patients’ management in a simplified pathway by increasing screening procedures and access to pangenotypic treatments mainly in the “reservoir” population of people who inject drugs and migrants. Even in the complex pathway of patients with previous comorbidities, AFEF takes the option of a therapeutic simplification. The EASL guidelines position themselves on the state of the art with a precise description of all therapeutic options available, without separating simplified and complex pathways even if they take into account the epidemiological evolution of difficult-to-treat populations. Baishideng Publishing Group Inc 2018-10-27 2018-10-27 /pmc/articles/PMC6206148/ /pubmed/30386457 http://dx.doi.org/10.4254/wjh.v10.i10.639 Text en ©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. |
spellingShingle | Editorial Loustaud-Ratti, Véronique Debette-Gratien, Marilyne Carrier, Paul European Association for the Study of the Liver and French hepatitis C recent guidelines: The paradigm shift |
title | European Association for the Study of the Liver and French hepatitis C recent guidelines: The paradigm shift |
title_full | European Association for the Study of the Liver and French hepatitis C recent guidelines: The paradigm shift |
title_fullStr | European Association for the Study of the Liver and French hepatitis C recent guidelines: The paradigm shift |
title_full_unstemmed | European Association for the Study of the Liver and French hepatitis C recent guidelines: The paradigm shift |
title_short | European Association for the Study of the Liver and French hepatitis C recent guidelines: The paradigm shift |
title_sort | european association for the study of the liver and french hepatitis c recent guidelines: the paradigm shift |
topic | Editorial |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206148/ https://www.ncbi.nlm.nih.gov/pubmed/30386457 http://dx.doi.org/10.4254/wjh.v10.i10.639 |
work_keys_str_mv | AT loustaudrattiveronique europeanassociationforthestudyoftheliverandfrenchhepatitiscrecentguidelinestheparadigmshift AT debettegratienmarilyne europeanassociationforthestudyoftheliverandfrenchhepatitiscrecentguidelinestheparadigmshift AT carrierpaul europeanassociationforthestudyoftheliverandfrenchhepatitiscrecentguidelinestheparadigmshift |